Short answer: the D'Altilio 2007 UC-II study was a 120-day, double-blind trial in 20 arthritic dogs. Dogs given 10 mg of undenatured type II collagen daily showed significant pain reductions (62% overall pain at 120 days), while 2,000 mg glucosamine + 1,600 mg chondroitin produced improvement that was not statistically significant.
That single sentence is quoted constantly in joint-supplement marketing, usually without the parts that matter: five dogs per group, subjective pain scoring, and funding from the company that sells UC-II. This page walks through the D'Altilio 2007 UC-II study exactly as it was run — protocol, numbers, safety data, what replicated, and what it genuinely does not prove.
What was the D'Altilio 2007 UC-II study?
The paper is D'Altilio M, Peal A, Alvey M, Simms C, Curtsinger A, Gupta RC, Canerdy TD, Goad JT, Bagchi M, Bagchi D, 'Therapeutic Efficacy and Safety of Undenatured Type II Collagen Singly or in Combination with Glucosamine and Chondroitin in Arthritic Dogs,' Toxicology Mechanisms and Methods 2007;17(4):189–196 (PMID 20020968). The work was carried out at Murray State University's Breathitt Veterinary Center in Kentucky.
Twenty adult dogs were enrolled on the basis of moderate arthritis signs — joint stiffness, lameness, swollen joints, difficulty getting up or down and walking short stairways. Dogs with other serious disease, including hepatic or renal disease, were excluded, and none received NSAIDs for three to four weeks before or during the study. Owners consented; the design was double-blind, with neither investigators nor owners knowing capsule contents.
The four treatment groups
| Group | Daily oral treatment | Dogs |
|---|---|---|
| I | Placebo | 5 |
| II | 10 mg active UC-II (glycosylated undenatured type II collagen) | 5 |
| III | 2,000 mg glucosamine HCl + 1,600 mg chondroitin sulfate | 5 |
| IV | 10 mg UC-II + 2,000 mg glucosamine + 1,600 mg chondroitin | 5 |
Treatment ran for 120 days, followed by a 30-day withdrawal period — dogs were assessed monthly across a total of 150 days. So the headline '10 mg versus 2,000 mg' is accurate as far as glucosamine goes; the full comparator was 3,600 mg of glucosamine plus chondroitin.
How pain was measured
Three separate outcomes were scored monthly by observation: overall pain (trouble standing after sitting, vocalization, crying) on a 0–10 scale; pain upon limb manipulation, judged during extension and flexion of all four limbs, on a 0–4 scale; and exercise-associated lameness after physical exertion (limping, holding a limb up, rigidity), also 0–4. Blood was drawn monthly for ALT and bilirubin (liver) and BUN and creatinine (kidney), and body weight was recorded.
What did the D'Altilio 2007 study find?
Placebo dogs showed no significant change in arthritic signs at any point. In the UC-II group, overall pain fell significantly within 30 days, and the limb-manipulation and lameness scores followed by day 60. The largest reductions came at the end of the 120-day treatment period.
| Outcome | UC-II alone (group II) | Glucosamine + chondroitin (group III) | All three combined (group IV) |
|---|---|---|---|
| Overall pain, day 30 | −33% (significant) | Some relief, not significant (p > 0.05) | — |
| Pain on limb manipulation, day 60 | −66% | Some relief, not significant | — |
| Exercise-associated lameness, day 60 | −44% | Some relief, not significant | — |
| Overall pain, day 120 | −62% | Some relief, not significant | −57% |
| Pain on limb manipulation, day 120 | −91% | Some relief, not significant | −53% |
| Exercise-associated lameness, day 120 | −78% | Some relief, not significant | −53% |
All percentages are reductions from each group's own pre-treatment baseline, not head-to-head differences between groups. The authors did report that overall activity in group IV was significantly better than in group III, and concluded that glucosamine and chondroitin 'alleviated some pain but not significantly.'
Want daily support for your dog’s joints, skin, and coat?
Explore Pure Majesty Pets Liquid Collagen for Dogs, a weight-adjustable liquid formula for everyday mobility, skin, and coat support.
Discover Liquid Collagen for Dogs →
For supportive care; not a substitute for veterinary diagnosis or prescribed treatment.
Two further findings deserve as much attention as the pain numbers. First, after supplements were withdrawn for 30 days, dogs in groups II, III and IV all relapsed — pain and lameness returned, which is why the authors concluded continuous treatment is required. Second, on safety: no dog showed adverse effects, and ALT, bilirubin, BUN and creatinine stayed within normal limits throughout. Body weight held steady in the supplemented groups while the placebo group gained roughly 14% of its starting weight, which the authors read as a sign the untreated dogs simply moved less.
Why would 10 mg of UC-II compare with 3,600 mg of glucosamine and chondroitin?
Because the two are not the same kind of ingredient. Glucosamine is an amino-monosaccharide precursor of glycosaminoglycans, the ground substance of articular cartilage; chondroitin sulfate is part of the proteoglycan that gives cartilage its elasticity. Both are supplied as raw material, which is why doses are measured in grams.
Undenatured type II collagen is dosed as an immunological signal instead. The D'Altilio authors describe it working through oral tolerization: small oral amounts of intact type II collagen pass the Peyer's patches, lymphoid tissue surrounding the small intestine that screens incoming proteins and helps switch immune responses toward tolerance rather than attack. In this model, the immune system stops targeting the type II collagen in the dog's own joint cartilage. That pathway is why the trials use 10 mg of active collagen rather than grams, and why the collagen must stay undenatured — hydrolyzed collagen has lost the triple-helical shape the mechanism depends on.
Worth flagging honestly: oral tolerance is a plausible, widely cited mechanism with supporting work in human autoimmune research (Trentham et al., Science 1993), but this trial measured pain scores, not immune markers. The mechanism is inferred here, not demonstrated.
What the D'Altilio 2007 study does not prove
This is the section most summaries skip. Taking the trial at face value overstates it in five ways.
- Five dogs per group. Twenty dogs total is a pilot-scale sample. Small groups make estimates unstable and percentage changes look dramatic.
- Subjective endpoints. All three outcomes were observational scores on short ordinal scales. Blinding protects against bias, but scored observation is far less precise than gait analysis.
- Within-group comparisons. The reported percentages are versus each group's own baseline. The paper does not present a statistical head-to-head of UC-II against glucosamine plus chondroitin on those pain scales — the fair statement is that UC-II reached significance and the glucosamine arm did not.
- Sponsor involvement. The study was supported by InterHealth Nutraceuticals, the supplier of the UC-II used, and two co-authors were affiliated with that company. Industry funding does not invalidate research, but it belongs in the reader's assessment.
- No claim of disease reversal. Nothing here shows cartilage regrowth, radiographic change or slowed disease progression. Dogs relapsed within 30 days of stopping — evidence of symptom management, not repair.
What it does support, reasonably: at 10 mg/day for 120 days, UC-II was well tolerated in arthritic dogs, with no liver or kidney signal, and was associated with meaningful improvement in owner- and clinician-observed pain.
Has the D'Altilio study been replicated in dogs?
Partly, and mostly by the same research group — which is itself a limitation.
- DeParle et al., 2005 — the 90-day pilot that preceded it, comparing 1 mg and 10 mg daily UC-II in arthritic dogs (Journal of Veterinary Pharmacology and Therapeutics 28:385–390). The 10 mg dose performed better, which is where the 10 mg figure comes from.
- Gupta et al., 2012 — the most important follow-up, because it added an objective measure. Groups of 7–10 moderately arthritic dogs received the same four treatments for 150 days, and pain was assessed with a piezoelectric ground force plate (peak vertical force and impulse area) alongside observational scales (Journal of Animal Physiology and Animal Nutrition 96:770–777). Force-plate data removes much of the observer subjectivity that weakens the 2007 paper.
- Independent work is more recent and still limited. A 2024 randomized, double-blind, placebo-controlled cross-over study in PLOS ONE tested a feed supplement containing UC-II and Boswellia serrata in dogs with mild-to-moderate mobility disorders — a combination product, so it cannot isolate UC-II. A 2024 review in the Journal of Small Animal Practice surveying non-pharmaceutical, non-surgical treatments for canine osteoarthritis places UC-II among the nutraceuticals with promising but not definitive evidence.
Honest summary of the state of play: research suggests UC-II may support joint comfort in arthritic dogs at 10 mg/day, replication outside the original group remains limited, and evidence for structural disease modification remains limited.
How to read any supplement trial like this one
The D'Altilio paper is a useful teaching case. Five questions handle most joint-supplement claims you'll meet on a label:
- How many animals? Under ten per group is a pilot. Treat the effect size as a signal, not a settled number.
- Objective or observed? Force plates, accelerometers and validated owner questionnaires beat unstructured scoring.
- Compared with what? A change from baseline is not the same as beating a comparator.
- Who paid? Look for the funding statement and author affiliations — both are printed in the paper.
- Reproduced by whom? Independent replication carries more weight than repeated work by one team.
If you want the wider evidence map for the ingredients on your dog's label, our dog joint and hip health guide covers how the main joint actives compare, and our breakdown of glucosamine and chondroitin for dogs deals specifically with the comparator arm used in this trial.
When should you talk to a vet instead of reaching for a supplement?
UC-II is not a painkiller, and nothing in this research supports using it in place of veterinary care. Book an appointment if your dog is limping persistently or non-weight-bearing, yelps when a joint is handled, has sudden swelling or heat in a joint, loses appetite or weight, or has a known kidney, liver or autoimmune condition. Also check in before combining supplements with NSAIDs or other prescribed medication.
Not sure whether what you're seeing is joint pain at all? Work through the early signs of arthritis in dogs first, and if your dog is over seven, our guide to the best joint supplement for senior dogs sets realistic expectations for what daily supplementation can and cannot do.
What this means when you read a joint supplement label
The trial dose is 10 mg of active undenatured type II collagen daily, sustained — the improvements were largest at 120 days and disappeared within 30 days of stopping. So the practical questions are whether a product states the active UC-II amount rather than burying it in a blend, and whether you can realistically give it every day for months.
Pure Majesty Pets includes UC-II undenatured type II collagen in our hip and joint supplement for dogs, alongside glucosamine HCl, chondroitin sulfate, MSM, green-lipped mussel and hyaluronic acid — 18 actives in one daily chew rather than the two most chews stop at. For dogs who refuse chews or need dosing by dropper, our liquid glucosamine for dogs delivers the glucosamine–chondroitin–MSM core in a pre-dissolved liquid. Both sit in our dog joint and hip supplements range. If your dog is already on medication, or you're comparing formats, our look at Dasuquin vs Cosequin is a useful next read.
Frequently asked questions about the D'Altilio 2007 UC-II study
Did 10 mg of UC-II really beat 2,000 mg of glucosamine?
In this trial, UC-II at 10 mg/day produced statistically significant pain reductions from baseline while 2,000 mg glucosamine plus 1,600 mg chondroitin produced improvement that did not reach significance. The paper does not report a direct statistical head-to-head on those pain scales, so 'significant versus not significant' is the accurate framing.
How many dogs were in the D'Altilio 2007 study?
Twenty arthritic dogs, split into four groups of five, treated daily for 120 days with a 30-day withdrawal period afterwards.
Was the study independent?
No. It was conducted at Murray State University with support from InterHealth Nutraceuticals, which supplied the UC-II, and two co-authors were affiliated with that company.
What is the UC-II dosage for dogs used in the research?
10 mg of active undenatured type II collagen per day, given orally. The earlier 2005 pilot compared 1 mg with 10 mg and found the higher dose more effective. Dosage for an individual dog should be confirmed with your veterinarian.
How long does UC-II take to work in dogs?
In this trial, overall pain scores improved significantly within 30 days, limb-manipulation and lameness scores by 60 days, and the largest effects appeared at 120 days. Dogs relapsed within 30 days of stopping, so any benefit depends on continued daily use.
Does UC-II repair cartilage or cure arthritis in dogs?
No. This study measured observed pain and lameness, not joint structure, and the relapse after withdrawal points to symptom support rather than repair. Evidence for structural disease modification in dogs remains limited.
References
- D'Altilio M, Peal A, Alvey M, et al. Therapeutic Efficacy and Safety of Undenatured Type II Collagen Singly or in Combination with Glucosamine and Chondroitin in Arthritic Dogs. Toxicology Mechanisms and Methods. 2007;17(4):189–196. DOI: 10.1080/15376510600910469 · PMID 20020968.
- DeParle LA, Gupta RC, Canerdy TD, et al. Efficacy and safety of glycosylated undenatured type-II collagen (UC-II) in therapy of arthritic dogs. Journal of Veterinary Pharmacology and Therapeutics. 2005;28(4):385–390.
- Gupta RC, Canerdy TD, Lindley J, et al. Comparative therapeutic efficacy and safety of type-II collagen (UC-II), glucosamine and chondroitin in arthritic dogs: pain evaluation by ground force plate. Journal of Animal Physiology and Animal Nutrition. 2012;96(5):770–777. DOI: 10.1111/j.1439-0396.2011.01166.x.
- Stabile M, Fracassi L, Lacitignola L, et al. Effects of a feed supplement containing undenatured type II collagen (UC II) and Boswellia Serrata in the management of mild/moderate mobility disorders in dogs: a randomized, double-blind, placebo-controlled, cross-over study. PLOS ONE. 2024;19(10). DOI: 10.1371/journal.pone.0305697.
- Pye C, Clark N, Bruniges N, Peffers M, Comerford E. Current evidence for non-pharmaceutical, non-surgical treatments of canine osteoarthritis. Journal of Small Animal Practice. 2024;65(1):3–23. DOI: 10.1111/jsap.13670.
- Trentham DE, Dynesius-Trentham RA, Orav EJ, et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science. 1993;261(5129):1727–1730.
Veterinary disclaimer: this article is educational and does not replace veterinary diagnosis or treatment. Supplements are not medicines and are not intended to diagnose, treat, cure or prevent any disease. Speak with your veterinarian before starting any supplement, particularly if your dog is on medication, pregnant, or has a diagnosed liver, kidney or autoimmune condition.